Stonepine Capital Management’s AEON Biopharma AEON Stock Holding History

Stonepine Capital Management’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$638K	Buy	+2,125,748	New	+$657K	0.4%	49

Other funds holding AEON

Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return

DG Capital Management New York $451M AUM 20.71% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Formidable Asset Management Cincinnati, Ohio $680M AUM 8.59% 1-Year Est. Return

Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return

Beacon Wealthcare LLC Raleigh, North Carolina $315M AUM 8.23% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Stonepine Capital Management's AEON Position: Q3 2026 in Review

Stonepine Capital Management opened a new position in AEON Biopharma (AEON) in Q3 2026: 2,125,748 shares worth $638K. The stake represents 0.4% of the portfolio and ranks #49 among its holdings.

21 funds tracked by Wall St. Rank hold AEON as of Q3 2026.

Stonepine Capital Management held 2,125,748 shares of AEON Biopharma worth $638K as of Q3 2026.
AEON Biopharma was a new Stonepine Capital Management position in Q3 2026.
AEON Biopharma made up 0.4% of Stonepine Capital Management's portfolio in Q3 2026, its #49 holding.
21 funds tracked by Wall St. Rank held AEON Biopharma as of Q3 2026.

Based on Stonepine Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.